AUC-guided vancomycin dosing: what the 2020 guideline asks for and how hospitals implement it

What the 2020 guideline changed

In 2020, a consensus guideline published jointly by the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) fundamentally changed how vancomycin should be monitored in clinical practice.

The key recommendation: AUC/MIC-guided dosing should replace trough-based monitoring as the primary method for vancomycin therapeutic drug monitoring (TDM) in serious methicillin-resistant Staphylococcus aureus (MRSA) infections.

The guideline made the change on the basis of evidence that AUC-guided monitoring:

• More accurately predicts clinical efficacy
• Is associated with less vancomycin-associated acute kidney injury than trough-guided dosing (the meta-analytic evidence is graded low)
• Provides a more reliable pharmacokinetic/pharmacodynamic (PK/PD) target

The Problem with Trough-Based Monitoring

For decades, vancomycin dosing was guided by trough concentrations — a single blood level drawn just before the next dose. The target trough range of 15–20 mg/L was widely used, but this approach has significant limitations.

Troughs Are a Poor Surrogate for AUC

The trough concentration is only one point on the concentration-time curve. Two patients can have identical trough levels but vastly different AUC values depending on their clearance, volume of distribution, and dosing interval.

Higher Troughs Mean Higher Nephrotoxicity

Multiple studies have demonstrated that targeting higher trough concentrations (15–20 mg/L) is associated with increased rates of acute kidney injury (AKI). The 2020 guidelines specifically note that the previous trough-based approach "may have contributed to increased nephrotoxicity."

The Evidence for AUC Superiority

The pharmacokinetic/pharmacodynamic target that best predicts vancomycin efficacy against MRSA is the AUC/MIC ratio. The consensus target of AUC₂₄ 400–600 mg·h/L (assuming an MIC of 1 mg/L) provides:

• Optimal bactericidal activity against MRSA
• Reduced nephrotoxicity compared to trough-based targets
• More consistent drug exposure across diverse patient populations

How Bayesian Estimation Works

The guidelines recommend Bayesian approaches as the preferred method for AUC estimation. But what does this actually mean for clinical practice?

Population Priors

Bayesian estimation starts with a population pharmacokinetic (PK) model — a mathematical description of how vancomycin behaves in a typical patient, based on large datasets. The Colin 2019 model, for example, describes vancomycin disposition using a two-compartment model with four parameters: clearance (CL), central volume (V1), intercompartmental clearance (Q), and peripheral volume (V2).

Individual Updating

When you measure a vancomycin level in your patient, the Bayesian algorithm updates the population prediction with this patient-specific information. This is called maximum a posteriori (MAP) estimation — it finds the set of PK parameters that best explains both the population data and the observed drug level.

Why It Matters Clinically

Bayesian estimation provides several advantages over traditional methods:

• Works with limited data: You can estimate AUC with just one measured level (or even zero levels using population priors alone)
• Accounts for patient-specific factors: Age, weight, renal function, and other covariates are incorporated directly
• Provides individual PK parameters: Clinicians get a complete pharmacokinetic profile, not just a single number

Why adoption has been slow at community hospitals

Three reasons come up repeatedly in surveys and in conversations with pharmacy directors.

Cost. The established Bayesian platforms are priced and implemented for large health systems, and their pricing is quote-based. A community hospital with a small pharmacy informatics budget often cannot justify the spend before it has seen local data.

Familiarity. Many pharmacists were trained on trough-based monitoring. Bayesian estimation is not difficult to use, but it is different, and a department needs training time and a protocol before it changes practice.

Reviewability. Some tools show a recommendation without the prior, the fit, or the equations behind it. A P&T committee that asks "how was this number produced?" needs an answer.

Where Vancomyzer fits

Vancomyzer is one option for the third problem in particular. It publishes the Colin 2019 population model it uses, the equations, the Bayesian settings, and every check that has been run; access to Vancomyzer is currently free. Open the calculator. It has not been validated in real patients, and no claim is made that it improves outcomes. Whether it fits a given hospital depends on the evaluation the hospital runs.

Getting started

1. Document the current state. Which monitoring method is in use, what the P&T committee requires, and what the baseline nephrotoxicity rate is.
2. Evaluate tools on evidence, transparency, cost and implementation effort, not on any one of them alone. Ask every vendor for the published model, the validation studies, and the regulatory classification.
3. Agree a protocol before touching patient data. For Vancomyzer, start with a feasibility discussion; protocol, endpoints, approvals and data handling are agreed first.
4. Train the team on the principles above and on the tool the hospital chooses.

References

1. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline. Am J Health-Syst Pharm. 2020;77(11):835–864. PMID: 32191793. doi:10.1093/ajhp/zxaa036
2. Colin PJ, Allegaert K, Thomson AH, et al. Vancomycin pharmacokinetics throughout life: Results from a pooled population analysis. Clin Pharmacokinet. 2019;58(6):767–780. PMID: 30656565. doi:10.1007/s40262-018-0727-5
3. Abdelmessih E, Patel N, Vekaria J, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis. Pharmacotherapy. 2022;42(9):741–753. PMID: 35869689. doi:10.1002/phar.2722
4. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity. Clin Infect Dis. 2009;49(4):507–514. PMID: 19586413. doi:10.1086/600884
5. Hall NM, Brown ML, Edwards WS, et al. Model-informed precision dosing improves outcomes in patients receiving vancomycin for gram-positive infections. Open Forum Infect Dis. 2024;11(1):ofae002. PMID: 38250202. doi:10.1093/ofid/ofae002